Cell Growth & Differentiation, Vol 9, Issue 1 49-58, Copyright © 1998 by American Association of Cancer Research

ARTICLES

Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor

P Lin, S Sankar, S Shan, MW Dewhirst, PJ Polverini, TQ Quinn and KG Peters
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

Vascular endothelial growth factor (VEGF) is a leading candidate for an endogenous mediator of tumor angiogenesis. Recently, two endothelial cell surface receptors, flk-1 and flt-1, have been shown to mediate the angiogenic activities of VEGF. In this study, we have evaluated whether a soluble VEGF receptor could suppress tumor angiogenesis and thereby inhibit tumor growth. A soluble VEGF receptor was constructed by fusing the entire extracellular domain of murine flk-1 to a six-histidine tag at the COOH terminus (ExFlk.6His). In vitro, recombinant ExFlk.6His protein bound VEGF with high affinity (Kd, 16 nM) and blocked receptor activation in a dose-dependent manner and inhibited VEGF-induced endothelial cell proliferation and migration. ExFlk.6His bound to endothelial cells only in the presence of VEGF, and cell surface cross-linking yielded a high molecular weight complex consistent with the VEGF-mediated formation of a heterodimer between ExFlk.6His and the endogenous VEGF receptor. In vivo, ExFlk.6His potently inhibited corneal neovascularization induced by conditioned media from a rat mammary carcinoma cell line (R3230AC). Moreover, when ExFlk.6His protein was administered into a cutaneous tumor window chamber concomitantly with R3230AC carcinoma transplants, tumor growth was inhibited by 75% (P < 0.005) and vascular density was reduced by 50% (P < 0.002) compared with control-treated tumors. These results demonstrate the potential of ExFlk.6His to inhibit VEGF action by a potent "dominant-negative" mechanism and suggest that targeting VEGF action using a soluble receptor may be an effective antiangiogenic therapy for cancer and other "angiogenic" diseases.

This article has been cited by other articles:

				D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K.-H. Thierauch, and C. Cursiefen Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1836 - 1842. [Abstract] [Full Text] [PDF]

				P. Sini, I. Samarzija, F. Baffert, A. Littlewood-Evans, C. Schnell, A. Theuer, S. Christian, A. Boos, H. Hess-Stumpp, J. A. Foekens, et al. Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics Cancer Res., March 1, 2008; 68(5): 1581 - 1592. [Abstract] [Full Text] [PDF]

				E. Geretti, A. Shimizu, P. Kurschat, and M. Klagsbrun Site-directed Mutagenesis in the B-Neuropilin-2 Domain Selectively Enhances Its Affinity to VEGF165, but Not to Semaphorin 3F J. Biol. Chem., August 31, 2007; 282(35): 25698 - 25707. [Abstract] [Full Text] [PDF]

				J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells Cancer Res., April 15, 2007; 67(8): 3683 - 3690. [Abstract] [Full Text] [PDF]

				Y. Cao, P. Sonveaux, S. Liu, Y. Zhao, J. Mi, B. M. Clary, C.-Y. Li, C. D. Kontos, and M. W. Dewhirst Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth Cancer Res., April 15, 2007; 67(8): 3835 - 3844. [Abstract] [Full Text] [PDF]

				D. Menendez, A. Inga, J. Snipe, O. Krysiak, G. Schonfelder, and M. A. Resnick A Single-Nucleotide Polymorphism in a Half-Binding Site Creates p53 and Estrogen Receptor Control of Vascular Endothelial Growth Factor Receptor 1 Mol. Cell. Biol., April 1, 2007; 27(7): 2590 - 2600. [Abstract] [Full Text] [PDF]

				L. Li, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-{kappa}B Transcriptional Activity Clin. Cancer Res., April 1, 2007; 13(7): 2178 - 2190. [Abstract] [Full Text] [PDF]

				N. Singh, P. D. Jani, T. Suthar, S. Amin, and B. K. Ambati Flt-1 Intraceptor Induces the Unfolded Protein Response, Apoptotic Factors, and Regression of Murine Injury-Induced Corneal Neovascularization Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4787 - 4793. [Abstract] [Full Text] [PDF]

				Y. Luo, Y.-J. Wen, Z.-Y. Ding, C.-H. Fu, Y. Wu, J.-Y. Liu, Q. Li, Q.-M. He, X. Zhao, Y. Jiang, et al. Immunotherapy of tumors with protein vaccine based on chicken homologous tie-2. Clin. Cancer Res., March 15, 2006; 12(6): 1813 - 1819. [Abstract] [Full Text] [PDF]

				R. Zent and A. Pozzi Antiangiogenic Therapy in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 325 - 327. [Full Text] [PDF]

				A. Shrivastava, M.A. von Wronski, A.K. Sato, D.T. Dransfield, D. Sexton, N. Bogdan, R. Pillai, P. Nanjappan, B. Song, E. Marinelli, et al. A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases Protein Eng. Des. Sel., September 1, 2005; 18(9): 417 - 424. [Abstract] [Full Text] [PDF]

				P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532. [Abstract] [Full Text] [PDF]

				N. Singh, S. Amin, E. Richter, S. Rashid, V. Scoglietti, P. D. Jani, J. Wang, R. Kaur, J. Ambati, Z. Dong, et al. Flt-1 Intraceptors Inhibit Hypoxia-Induced VEGF Expression In Vitro and Corneal Neovascularization In Vivo Invest. Ophthalmol. Vis. Sci., May 1, 2005; 46(5): 1647 - 1652. [Abstract] [Full Text] [PDF]

				K. Schmidt, J. Hoffend, A. Altmann, L. G. Strauss, A. Dimitrakopoulou-Strauss, B. Engelhardt, D. Koczan, J. Peter, S. Vorwald, H. Eskerski, et al. Transfer of the sFLT-1 Gene in Morris Hepatoma Results in Decreased Growth and Perfusion and Induction of Genes Associated with Stress Response Clin. Cancer Res., March 15, 2005; 11(6): 2132 - 2140. [Abstract] [Full Text] [PDF]

				K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593. [Abstract] [Full Text] [PDF]

				B. Z. Olenyuk, G.-J. Zhang, J. M. Klco, N. G. Nickols, W. G. Kaelin Jr., and P. B. Dervan Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist PNAS, November 30, 2004; 101(48): 16768 - 16773. [Abstract] [Full Text] [PDF]

				I. Shiojima and K. Walsh The Role of Vascular Endothelial Growth Factor in Restenosis: The Controversy Continues Circulation, October 19, 2004; 110(16): 2283 - 2286. [Full Text] [PDF]

				A. L. Rakhmilevich, A. T. Hooper, D. J. Hicklin, and P. M. Sondel Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody Mol. Cancer Ther., August 1, 2004; 3(8): 969 - 976. [Abstract] [Full Text] [PDF]

				J. M.L. Ebos, G. Bocci, S. Man, P. E. Thorpe, D. J. Hicklin, D. Zhou, X. Jia, and R. S. Kerbel A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma Mol. Cancer Res., June 1, 2004; 2(6): 315 - 326. [Abstract] [Full Text] [PDF]

				N. H. Fernando and H. I. Hurwitz Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 11 - 18. [Abstract] [Full Text] [PDF]

				R. Shao, S. Bao, X. Bai, C. Blanchette, R. M. Anderson, T. Dang, M. L. Gishizky, J. R. Marks, and X.-F. Wang Acquired Expression of Periostin by Human Breast Cancers Promotes Tumor Angiogenesis through Up-Regulation of Vascular Endothelial Growth Factor Receptor 2 Expression Mol. Cell. Biol., May 1, 2004; 24(9): 3992 - 4003. [Abstract] [Full Text] [PDF]

				G. Zadeh, B. Qian, A. Okhowat, N. Sabha, C. D. Kontos, and A. Guha Targeting the Tie2/Tek Receptor in Astrocytomas Am. J. Pathol., February 1, 2004; 164(2): 467 - 476. [Abstract] [Full Text] [PDF]

				K. G. Peters, C. D. Kontos, P. C. Lin, A. L. Wong, P. Rao, L. Huang, M. W. Dewhirst, and S. Sankar Functional Significance of Tie2 Signaling in the Adult Vasculature Recent Prog. Horm. Res., January 1, 2004; 59(1): 51 - 71. [Abstract] [Full Text]

				H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]

				P. J. Mahasreshti, M. Kataram, M. H. Wang, C. R. Stockard, W. E. Grizzle, D. Carey, G. P. Siegal, H. J. Haisma, R. D. Alvarez, and D. T. Curiel Intravenous Delivery of Adenovirus-mediated Soluble FLT-1 Results in Liver Toxicity Clin. Cancer Res., July 1, 2003; 9(7): 2701 - 2710. [Abstract] [Full Text] [PDF]

				N. Cheng, D. M. Brantley, H. Liu, Q. Lin, M. Enriquez, N. Gale, G. Yancopoulos, D. P. Cerretti, T. O. Daniel, and J. Chen Blockade of EphA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis Mol. Cancer Res., November 1, 2002; 1(1): 2 - 11. [Abstract] [Full Text] [PDF]

				W. W. Spurbeck, C. Y. C. Ng, T. S. Strom, E. F. Vanin, and A. M. Davidoff Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model Blood, October 16, 2002; 100(9): 3361 - 3368. [Abstract] [Full Text] [PDF]

				A. Stopeck, M. Sheldon, M. Vahedian, G. Cropp, R. Gosalia, and A. Hannah Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies Clin. Cancer Res., September 1, 2002; 8(9): 2798 - 2805. [Abstract] [Full Text] [PDF]

				E. Edwards, L. Geng, J. Tan, H. Onishko, E. Donnelly, and D. E. Hallahan Phosphatidylinositol 3-Kinase/Akt Signaling in the Response of Vascular Endothelium to Ionizing Radiation Cancer Res., August 15, 2002; 62(16): 4671 - 4677. [Abstract] [Full Text] [PDF]

				A. M. Davidoff, A. C. Nathwani, W. W. Spurbeck, C. Y. C. Ng, J. Zhou, and E. F. Vanin rAAV-mediated Long-term Liver-generated Expression of an Angiogenesis Inhibitor Can Restrict Renal Tumor Growth in Mice Cancer Res., June 1, 2002; 62(11): 3077 - 3083. [Abstract] [Full Text] [PDF]

				T. Maeno, T. Tanaka, Y. Sando, T. Suga, Y. Maeno, J. Nakagawa, T. Hosono, M. Sato, H. Akiyama, S. Kishi, et al. Stimulation of Vascular Endothelial Growth Factor Gene Transcription by all trans Retinoic Acid through Sp1 and Sp3 Sites in Human Bronchioloalveolar Carcinoma Cells Am. J. Respir. Cell Mol. Biol., February 1, 2002; 26(2): 246 - 253. [Abstract] [Full Text] [PDF]

				A. M. Davidoff, C. Y. C. Ng, P. Brown, M. A. Leary, W. W. Spurbeck, J. Zhou, E. Horwitz, E. F. Vanin, and A. W. Nienhuis Bone Marrow-derived Cells Contribute to Tumor Neovasculature and, When Modified to Express an Angiogenesis Inhibitor, Can Restrict Tumor Growth in Mice Clin. Cancer Res., September 1, 2001; 7(9): 2870 - 2879. [Abstract] [Full Text] [PDF]

				S. Shan, A. C. Lockhart, W. Y. Saito, A. M. Knapp, K. R. Laderoute, and M. W. Dewhirst The Novel Tubulin-binding Drug BTO-956 Inhibits R3230Ac Mammary Carcinoma Growth and Angiogenesis in Fischer 344 Rats Clin. Cancer Res., August 1, 2001; 7(8): 2590 - 2596. [Abstract] [Full Text] [PDF]

				A. L. Harris, P. Reusch, B. Barleon, C. Hang, N. Dobbs, and D. Marme Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy Clin. Cancer Res., July 1, 2001; 7(7): 1992 - 1997. [Abstract] [Full Text] [PDF]

				P. J. Mahasreshti, J. G. Navarro, M. Kataram, M. H. Wang, D. Carey, G. P. Siegal, M. N. Barnes, D. M. Nettelbeck, R. D. Alvarez, A. Hemminki, et al. Adenovirus-mediated Soluble FLT-1 Gene Therapy for Ovarian Carcinoma Clin. Cancer Res., July 1, 2001; 7(7): 2057 - 2066. [Abstract] [Full Text] [PDF]

				Q. Shi, X. Le, J. L. Abbruzzese, Z. Peng, C.-N. Qian, H. Tang, Q. Xiong, B. Wang, X.-C. Li, and K. Xie Constitutive Sp1 Activity Is Essential for Differential Constitutive Expression of Vascular Endothelial Growth Factor in Human Pancreatic Adenocarcinoma Cancer Res., May 1, 2001; 61(10): 4143 - 4154. [Abstract] [Full Text]

				M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, G. Trinchieri, C. M. Sehgal, M. D. Feldman, and W. M. F. Lee Doppler Ultrasound Imaging Detects Changes in Tumor Perfusion during Antivascular Therapy Associated with Vascular Anatomic Alterations Cancer Res., April 1, 2001; 61(7): 2974 - 2982. [Abstract] [Full Text]

				M. J. Currie, S. P. Gunningham, C. Han, P. A. E. Scott, B. A. Robinson, A. L. Harris, and S. B. Fox Angiopoietin-1 Is Inversely Related to Thymidine Phosphorylase Expression in Human Breast Cancer, Indicating a Role in Vascular Remodeling Clin. Cancer Res., April 1, 2001; 7(4): 918 - 927. [Abstract] [Full Text]

				C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer PNAS, March 22, 2001; (2001) 81615298. [Abstract] [Full Text]

				L. Geng, E. Donnelly, G. McMahon, P. C. Lin, E. Sierra-Rivera, H. Oshinka, and D. E. Hallahan Inhibition of Vascular Endothelial Growth Factor Receptor Signaling Leads to Reversal of Tumor Resistance to Radiotherapy Cancer Res., March 1, 2001; 61(6): 2413 - 2419. [Abstract] [Full Text]

				A. Compagni, P. Wilgenbus, M.-A. Impagnatiello, M. Cotten, and G. Christofori Fibroblast Growth Factors Are Required for Efficient Tumor Angiogenesis Cancer Res., December 1, 2000; 60(24): 7163 - 7169. [Abstract] [Full Text]

				S. Yano, H. Shinohara, R. S. Herbst, H. Kuniyasu, C. D. Bucana, L. M. Ellis, D. W. Davis, D. J. McConkey, and I. J. Fidler Expression of Vascular Endothelial Growth Factor Is Necessary but not Sufficient for Production and Growth of Brain Metastasis Cancer Res., September 1, 2000; 60(17): 4959 - 4967. [Abstract] [Full Text]

				K. Takayama, H. Ueno, Y. Nakanishi, T. Sakamoto, K. Inoue, K. Shimizu, H. Oohashi, and N. Hara Suppression of Tumor Angiogenesis and Growth by Gene Transfer of a Soluble Form of Vascular Endothelial Growth Factor Receptor into a Remote Organ Cancer Res., April 1, 2000; 60(8): 2169 - 2177. [Abstract] [Full Text]

				J. M. Wood, G. Bold, E. Buchdunger, R. Cozens, S. Ferrari, J. Frei, F. Hofmann, J. Mestan, H. Mett, T. O’Reilly, et al. PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Res., April 1, 2000; 60(8): 2178 - 2189. [Abstract] [Full Text]

				G. McMahon VEGF Receptor Signaling in Tumor Angiogenesis Oncologist, April 1, 2000; 5(90001): 3 - 10. [Abstract] [Full Text]

				S. Yano, R. S. Herbst, H. Shinohara, B. Knighton, C. D. Bucana, J. J. Killion, J. Wood, and I. J. Fidler Treatment for Malignant Pleural Effusion of Human Lung Adenocarcinoma by Inhibition of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Phosphorylation Clin. Cancer Res., March 1, 2000; 6(3): 957 - 965. [Abstract] [Full Text]

				S. R. Wedge, D. J. Ogilvie, M. Dukes, J. Kendrew, J. O. Curwen, L. F. Hennequin, A. P. Thomas, E. S. E. Stokes, B. Curry, G. H. P. Richmond, et al. ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-Spectrum Antitumor Efficacy Cancer Res., February 1, 2000; 60(4): 970 - 975. [Abstract] [Full Text]

				E. I. Salim, H. Wanibuchi, K. Morimura, S. Kim, Y. Yano, S. Yamamoto, and S. Fukushima Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine Carcinogenesis, February 1, 2000; 21(2): 195 - 203. [Abstract] [Full Text] [PDF]

				C.-Y. Li, S. Shan, Q. Huang, R. D. Braun, J. Lanzen, K. Hu, P. Lin, and M. W. Dewhirst Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via Skin Window Chambers in Rodent Models J Natl Cancer Inst, January 19, 2000; 92(2): 143 - 147. [Abstract] [Full Text] [PDF]

				T. Veikkola, M. Karkkainen, L. Claesson-Welsh, and K. Alitalo Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors Cancer Res., January 1, 2000; 60(2): 203 - 212. [Full Text]

				M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, et al. Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors Cancer Res., October 1, 1999; 59(20): 5209 - 5218. [Abstract] [Full Text] [PDF]

				G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J, January 1, 1999; 13(1): 9 - 22. [Abstract] [Full Text]

				A. Stratmann, W. Risau, and K. H. Plate Cell Type-Specific Expression of Angiopoietin-1 and Angiopoietin-2 Suggests a Role in Glioblastoma Angiogenesis Am. J. Pathol., November 1, 1998; 153(5): 1459 - 1466. [Abstract] [Full Text] [PDF]

				S. Zaina, R. V. S. Newton, M. R. Paul, and C. F. Graham Local Reduction of Organ Size in Transgenic Mice Expressing a Soluble Insulin-Like Growth Factor II/Mannose-6-Phosphate Receptor Endocrinology, September 1, 1998; 139(9): 3886 - 3895. [Abstract] [Full Text] [PDF]

				P. Lin, J. A. Buxton, A. Acheson, C. Radziejewski, P. C. Maisonpierre, G. D. Yancopoulos, K. M. Channon, L. P. Hale, M. W. Dewhirst, S. E. George, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2 PNAS, July 21, 1998; 95(15): 8829 - 8834. [Abstract] [Full Text] [PDF]

				M. L. Gagnon, D. R. Bielenberg, Z.'e. Gechtman, H.-Q. Miao, S. Takashima, S. Soker, and M. Klagsbrun Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity PNAS, March 14, 2000; 97(6): 2573 - 2578. [Abstract] [Full Text] [PDF]

				C. J. Kuo, F. Farnebo, E. Y. Yu, R. Christofferson, R. A. Swearingen, R. Carter, H. A. von Recum, J. Yuan, J. Kamihara, E. Flynn, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer PNAS, April 10, 2001; 98(8): 4605 - 4610. [Abstract] [Full Text] [PDF]